SureSeq™ Breast Cancer + CNV Panel
The SureSeq Breast Cancer + CNV Panel has been developed to provide comprehensive coverage of 7 key genes implicated in breast and ovarian cancer, including BRCA1 and BRCA2.
Detecting SNVs and indels, as well as exon-level to whole gene CNVs, the SureSeq Breast Cancer + CNV Panel provides researchers with a single NGS workflow to study clinically relevant aberrations and alleviates the burden of running multiple assays.
The SureSeq Breast Cancer + CNV Panel offers:
- Unparalleled uniformity and high depth of coverage — reliably detect germline variants in all exonic regions
- CNV detection ranging from loss of single exons to full gene deletions and duplications — profile your samples for CNVs in all 7 genes
- Time savings — streamline your laboratory workflow with a single NGS assay for a comprehensive profile of all variants of interest
- Complimentary Interpret NGS data analysis software — easy-to-use analysis solution for accurate detection of all variants in your panel
Table 1: The SureSeq Breast Cancer + CNV panel targets all exons in 7 key genes implicated in breast and ovarian cancer, detecting SNVs and indels, as well as CNVs.
Evidence-based content and unparalleled coverage uniformity
Loss-of-function mutations in BRCA1 and BRCA2 have been implicated in an increased risk for breast and ovarian cancer1,2. Screening for germline mutations in these genes allows research into familial risk of developing breast and ovarian cancer. Facilitated by OGT’s expert bait design, the hybridisation-based SureSeq Breast Cancer + CNV Panel delivers excellent coverage uniformity, allowing consistent detection of SNVs and indels (Figure 1).
Figure 1: Illustration of the excellent coverage uniformity across BRCA1 and BRCA2. [A] BRCA1 exons 9, 10 and 11 coverage and [B] BRCA2 exons 9, 10 and 11. Depth of coverage per base (grey). Gene coding region as defined by RefSeq (blue).
Reliable CNV detection
To gain a comprehensive picture of breast and ovarian cancer, researchers often have to employ different methods for investigating SNVs, indels, and CNVs. The SureSeq Breast Cancer + CNV Panel offers reliable CNV detection in all genes covered by the panel, ranging from single-exon events up to deletions and duplications of complete genes. The panel has been fully validated on germline samples, with CNV detection 100% concordant with MLPA data, providing researchers with a single NGS assay for profiling of CNVs in BRCA1, BRCA2 and 5 other key genes implicated in breast and ovarian cancer (Figures 2 - 3).
Figure 2: Detection of germline deletions in BRCA1 and BRCA2. [A] BRCA1 deletion of exon 20 (4.99kb) and [B] BRCA2 deletion of exons 14-17 (4.21kb).
Figure 3: Detection of germline duplications in TP53 and BRCA1. [A] TP53 duplication of exons 2-6 (2.99kb) and [B] BRCA1 duplication of exons 4-6 (2.45kb).
Complimentary Interpret NGS analysis software
Interpret is OGT’s powerful and easy-to-use NGS analysis solution, facilitating analysis and visualisation of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq panels, Interpret perfectly complements the SureSeq Breast Cancer + CNV Panel, delivering fast and accurate detection of all SNVs, indels and CNVs covered by the panel. Following detection, all variants can be easily visualised in the user-friendly variant browser, for an effortless translation of all your sequencing data into meaningful results.
Bespoke panel content
You never have to sequence genes you’re not interested in and can always modify each panel to what’s relevant to your research. If the SureSeq Breast Cancer + CNV Panel doesn’t meet your exact requirements, you can choose from our regularly updated, expert-curated library of pre-optimised cancer content to create your ideal custom SureSeq myPanel™ Breast and/or Ovarian Cancer Panel.
The SureSeq Breast Cancer + CNV Panel in numbers
|Number of genes||7|
|Mean target coverage||>1000x|
|Coverage uniformity||>99% of bases at >20% of mean target coverage|
|DNA input recommended||>250ng high quality DNA|
|Samples per MiSeq® v2 run||24 samples / run|
|SureSeq Breast Cancer + CNV Panel (16 reactions)||Enrichment baits sufficient for 16 samples; SureSeq Interpret Software||602028-16||Get a quote|
|SureSeq Breast Cancer + CNV Panel (96 reactions)||Enrichment baits sufficient for 96 samples; SureSeq Interpret Software||602028-96
||Get a quote
|SureSeq NGS Library Preparation Complete Solution (16)||Bundle of 1x SureSeq library preparation kit (16), containing adaptors, PCR primers and enzymes, 1x SureSeq NGS Index Kit – Collection A, 1x SureSeq Hyb & Wash Kit (16), 1x Dynabeads M270 Streptavidin (2ml) and 1x AMPure XP beads (10ml). Sufficient for 16 samples||500084||Get a quote|
|SureSeq NGS Library Preparation Complete Solution (48)||Bundle of 3x SureSeq NGS Library Preparation Kit (16), containing adaptors, PCR primers and enzymes, 1x SureSeq NGS Index Kit – Collection B, 3x SureSeq NGS Hyb & Wash Kit (16), 3x Dynabeads M270 Streptavidin (2ml)* and 3x AMPure XP beads (10ml)*. Sufficient for 48 samples||500085||Get a quote|
- Antoniou et al., Am J Hum Genet. 2003 Sep;73(3):709.
- King et al., Science. 2003;302:643–646
SureSeq: For Research Use Only; Not for Diagnostic Procedures. This webpage and its contents are © Oxford Gene Technology IP Limited – 2020. All rights reserved. OGT™ and SureSeq™ are trademarks of Oxford Gene Technology IP Limited. The SureSeq NGS Library Preparation Kit was jointly developed between Oxford Gene Technology and Bioline Reagents Limited. Dynabeads is a trademark of Thermo Fisher Scientific and AMPure® is a registered trademark of Beckman Coulter Inc.